stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Return on assets
BioCryst Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 September 2026 was −69.3%, down 121.9 percentage points from fiscal 2025 (52.5%). Over the past ten years it has ranged from −71.7% (fiscal 2020) to 52.5% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of −1.67% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 52.5% | 70.18 |
| FY2024 | −17.7% | 24.81 |
| FY2023 | −42.5% | 0.96 |
| FY2022 | −43.4% | (3.53) |
| FY2021 | −39.9% | 31.80 |
| FY2020 | −71.7% | (4.08) |
| FY2019 | −67.6% | (5.32) |
| FY2018 | −62.3% | (13.22) |
| FY2017 | −49.1% | 2.90 |
| FY2016 | −52.0% | (18.78) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ANIP ANI Pharmaceuticals, Inc. compare | 7.85% |
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −1.64% |
| TRLV Trulieve Cannabis Corp. compare | −17.6% |
| PRGO Perrigo Company plc compare | −20.2% |
| BCRX BioCryst Pharmaceuticals, Inc. | −69.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement